Supernus Pharmaceuticals, Inc. Financials

Market Capitalization $2.13 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	36.11
Forward PE	20.44
Price to Sales TTM	$3.27
Price to Book MRQ	$2.12
Enterprise to Revenue	2.71
Enterprise to EBITDA	12.28

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	9.16%
Operating Margin	16.13%
Return on Assets TTM	2.89%
Return on Equity TTM	6.22%

Income Statement

Revenue TTM	$651,971,968
Revenue per Share TTM	$11.88
Quarterly Revenue Growth	14.20%
Gross Profit TTM	$580,537,024
EBITDA	$169,242,000
Net Income to Common TTM	$59,712,000
Diluted EPS TTM	$1.07
Quarterly Earnings Growth YoY	14.17%

Balance Sheet

Total Cash MRQ	$403,209,984
Total Cash per Share MRQ	$7.30
Total Debt MRQ	$
Total Debt to Equity MRQ	3.79
Current Ratio MRQ	2.20
Book Value per Share MRQ	$18.24

Cash Flow

Operating Cash Flow TTM	$172,503,008
Levered Free Cash Flow TTM	$162,932,000

SUPN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	55,219,300
Float Shares	47,590,730
Avg 10 Volume	304,420
Avg 30 Volume	None
Shares Short	6,197,909
Short Ratio	17.25
Short % of Shares	17.08%
% Held by Insiders	5.07%
% Held by Institutions	113.21%

Stock Price Summary

Beta	0.87
Fifty Two Week Low	$25.53
Fifty Two Week High	$39.37
Fifty Two Week Change	24.59%
Day 50 MA	$36.77
Day 200 MA	$32.19

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date